Analyst: Kesimpta sales from Novartis slightly over expectations
Analysts had somewhat underestimated Novartis’ Q1 sales of multiple sclerosis drug Kesimpta. According to an equity analyst at Sydbank, this is an advantage for biotech firm Genmab, which is behind developing the drug and receives royalties from Novartis.
by marketwire, translated by daniel pedersen
In the first quarter of fiscal 2022, Genmab has received USD 19.5m from sales of multiple sclerosis drug Kesimpta, which has been licensed to Swiss firm Novartis.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novartis increases sales of Genmab-developed sclerosis drug
For subscribers
.jpg)
.jpg&w=384&q=75)
